Literature DB >> 2313975

Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure.

M Akmal1, S E Kasim, A R Soliman, S G Massry.   

Abstract

Hyperlipidemia is common in chronic renal failure (CRF), but the underlying mechanisms are not clearly defined. Certain data points toward a potential role for the state of secondary hyperparathyroidism of CRF in its pathogenesis. We examined the effects of parathyroid hormone (PTH) on lipid metabolism utilizing intravenous fat tolerance test (IVFTT) and post-heparin lipolytic activity in five normal dogs, in six animals with CRF and secondary hyperparathyroidism (NPX) and in six normocalcemic-thyroparathyroidectomized dogs (NPX-PTX) with comparable degree and duration of CRF. NPX dogs had fasting hypertriglyceridemia (82 + 6.0 mg/dl vs. 49 +/- 2.7 mg/dl in normal dogs, P less than 0.01), abnormal IVFTT, and reduced post-heparin plasma LPL activity (151 +/- 10 vs. 275 +/- 15 mumol fatty acids/ml/min in normal dogs, P less than 0.01). The NPX-PTX dogs had normal fasting levels of serum triglycerides (42 +/- 0.6 mg/dl), normal IVFTT, and normal post-heparin plasma LPL (317 +/- 19 mumol fatty acids/ml/min) despite CRF. Post-heparin HL activity in plasma was not different between NPX and NPX-TPX dogs. The results show that excess blood levels of PTH and not other consequences of CRF are mainly responsible for the abnormalities in lipid metabolism. The data are consistent with the notion that excess PTH reduces post-heparin LPL activity in plasma, which in turn results in impaired lipid removal from the circulation and consequently hyperlipidemia.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2313975     DOI: 10.1038/ki.1990.58

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  19 in total

1.  Lipoprotein lipase deficiency in chronic kidney disease is accompanied by down-regulation of endothelial GPIHBP1 expression.

Authors:  Nosratola D Vaziri; Jun Yuan; Zhenmin Ni; Susanne B Nicholas; Keith C Norris
Journal:  Clin Exp Nephrol       Date:  2011-10-19       Impact factor: 2.801

Review 2.  Lipid abnormalities in kidney disease and management strategies.

Authors:  Vishwam Pandya; Akhilesh Rao; Kunal Chaudhary
Journal:  World J Nephrol       Date:  2015-02-06

Review 3.  Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease.

Authors:  Nosratola D Vaziri
Journal:  Clin Exp Nephrol       Date:  2013-08-24       Impact factor: 2.801

Review 4.  Osteoporosis and atherosclerosis in chronic renal failure.

Authors:  Y Nishizawa; H Morii
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

Review 5.  Statins in the management of dyslipidemia associated with chronic kidney disease.

Authors:  Murray Epstein; Nosratola D Vaziri
Journal:  Nat Rev Nephrol       Date:  2012-02-21       Impact factor: 28.314

6.  Predicting hospital cost in CKD patients through blood chemistry values.

Authors:  Russell W Bessette; Randy L Carter
Journal:  BMC Nephrol       Date:  2011-12-01       Impact factor: 2.388

7.  Poor coronary collateral vessel development in patients with mild to moderate renal insufficiency.

Authors:  Shuang-lun Xie; Hai-yan Li; Bing-qing Deng; Nian-sang Luo; Deng-feng Geng; Jing-feng Wang; Ru-qiong Nie
Journal:  Clin Res Cardiol       Date:  2010-09-25       Impact factor: 5.460

8.  Effect of dialysis membranes on lipoprotein profile of serum in haemodialysed patients.

Authors:  E Kimak; J Solski; L Janicka; B Wojtysiak; M Zagojska
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

Review 9.  Causes of dysregulation of lipid metabolism in chronic renal failure.

Authors:  Nosratola D Vaziri
Journal:  Semin Dial       Date:  2009 Nov-Dec       Impact factor: 3.455

Review 10.  Reasons for the lack of salutary effects of cholesterol-lowering interventions in end-stage renal disease populations.

Authors:  Nosratola D Vaziri; Keith C Norris
Journal:  Blood Purif       Date:  2013-01-22       Impact factor: 2.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.